<prompt> Please answer with one of the option in the bracket. Write reasoning in between . Write answer in between .Q:Background and Methods:Aldosterone is important in the pathophysiology of heart failure. In a double-blind study, we enrolled 1,663 patients who had NYHA class III or IV heart failure, a left ventricular ejection fraction of no more than 35, and who were being treated with an angiotensin-converting-enzyme inhibitor, a loop diuretic, and in most cases digoxin. A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily and 841 to receive placebo. The primary endpoint was death from all causes.Results:The trial was discontinued early, after a mean follow-up period of 24 months, because an interim analysis determined that spironolactone was efficacious. There were 386 deaths in the placebo group 46 and 284 in the spironolactone group 35; relative risk of death, 0.70; 95 confidence interval, 0.60 to 0.82; P0.001. This 30 reduction in the risk of death among patients in the spironolactone group was attributed to a lower risk of both death from progressive heart failure and sudden death from cardiac causes. The frequency of hospitalization for worsening heart failure was 35 lower in the spironolactone group than in the placebo group relative risk of hospitalization, 0.65; 95 confidence interval, 0.54 to 0.77; P0.001. In addition, patients who received spironolactone had a significant improvement in the symptoms of heart failure, as assessed on the basis of the New York Heart Association functional class P0.001. Gynecomastia or breast pain was reported in 10 of men who were treated with spironolactone, as compared with 1 percent of men in the placebo group P0.001. The incidence of serious hyperkalemia was minimal in both groups of patients.To which of the following patients are the results of this clinical trial applicable?? A: An 82-year-old female with NYHA class II heart failure with an LVEF of 22, taking lisinopril, furosemide, and digoxin, B: A 65-year-old male with newly diagnosed NYHA class IV heart failure and a LVEF of 21, about to begin medical therapy, C: A 56-year-old male with NYHA class III heart failure with an LVEF of 32, current taking lisinopril, furosemide, and digoxin, D: An 86-year-old female recently found to have an LVEF of 34, currently taking furosemide and carvedilol, E: A 78-year-old male with NYHA class II heart failure and LVEF 36,  <response>: This is a multiple choice question about a clinical trial evaluating the efficacy of spironolactone in patients with severe heart failure already on standard therapy with ACE inhibitors, loop diuretics, and digoxin. The key details from the trial are:- Patients had NYHA class III or IV heart failure - LVEF 35- Already on ACE inhibitor, loop diuretic, and digoxin- Spironolactone reduced mortality and hospitalizations compared to placebo- Main side effect was gynecomastia in menTo identify the correct answer, I need to find the choice that describes a patient most similar to those enrolled in the original trial.C: A 56-year-old male with NYHA class III heart failure with an LVEF of 32, current taking lisinopril, furosemide, and digoxin 